Rebamipide May Be Comparable to H2 Receptor Antagonist in Healing Iatrogenic Gastric Ulcers Created by Endoscopic Mucosal Resection: A Prospective Randomized Pilot Study.
10.3346/jkms.2010.25.4.583
- Author:
Yu Jin KIM
1
;
Jae Hee CHEON
;
Sang Kil LEE
;
Jie Hyun KIM
;
Yong Chan LEE
Author Information
1. Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. geniushee@yuhs.ac
- Publication Type:Original Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Rebamipide;
Stomach Ulcer, Endoscopic Mucosal Resection;
H2 Receptor Antagonist
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Alanine/*analogs & derivatives/therapeutic use;
Anti-Ulcer Agents/*therapeutic use;
Endoscopy, Gastrointestinal/*adverse effects;
Famotidine/*therapeutic use;
Histamine H2 Antagonists/*therapeutic use;
Humans;
Iatrogenic Disease;
Male;
Middle Aged;
Pilot Projects;
Prospective Studies;
Quinolones/*therapeutic use;
Receptors, Histamine H2/metabolism;
Stomach Ulcer/*drug therapy/*etiology/pathology;
Wound Healing
- From:Journal of Korean Medical Science
2010;25(4):583-588
- CountryRepublic of Korea
- Language:English
-
Abstract:
Endoscopic mucosal resection (EMR) results in the formation of iatrogenic gastric ulcers and the optimal treatments for such ulcers are still unclear. We aimed to evaluate the efficacy of rebamipide in the management of EMR-induced ulcers by comparing it with an H2 receptor antagonist. After EMR, patients were randomly assigned into either rebamipide or famotidine groups. All patients received a one-week lansoprazole 30 mg q.d. therapy followed by three-week famotidine (20 mg b.i.d.) or rebamipide (100 mg t.i.d.) therapy. Four weeks after the treatments, ulcer sizes, stages, bleeding rates, and ulcer-related symptoms were compared using endoscopy and a questionnaire. A total of 63 patients were enrolled in this study. Finally, 51 patients were analyzed, 26 in rebamipide and 25 in famotidine group. Baseline characteristics were not significantly different between the two groups. Four weeks after EMR, the two groups were comparable in terms of ulcer reduction ratio (P=0.297), and ulcer stage (P=1.000). Moreover, no difference was observed with regard to ulcer-related symptoms, drug compliance, adverse drug event rates, and bleeding rates. Our data suggest that rebamipide is not inferior to famotidine in healing iatrogenic gastric ulcers, and could be a therapeutic option in the treatment of such ulcers.
